Literature DB >> 10430518

Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K).

J M Grubber1, A M Saunders, A R Crane-Gatherum, W K Scott, E R Martin, C S Haynes, P M Conneally, G W Small, A D Roses, J L Haines, M A Pericak-Vance.   

Abstract

Butyrylcholinesterase (BCHE) is an enzyme expressed in most human tissues. Recently, an increased odds of carrying the K variant of BCHE (BCHE-K) was reported among Alzheimer disease (AD) cases as compared with controls. We tested our data set of 245 sporadic AD cases and 241 controls for an association between BCHE-K, APOE4, and AD using logistic regression and chi-square analyses. The sib transmission disequilibrium test (S-TDT) was also used to test for differences in BCHE-K allele frequencies between 163 discordant sib-pairs selected from multiplex AD families. No statistically significant differences were noted between BCHE-K case and control allele frequencies even after stratifying by APOE4 status. S-TDT analysis between the BCHE-K variant and AD was also not significant (P = 0.52). We conclude that BCHE-K is not a major genetic risk factor for AD in our study population.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10430518     DOI: 10.1016/s0304-3940(99)00426-7

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

Review 1.  Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?

Authors:  E Giacobini
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  Association of BDNF and BCHE with Alzheimer's disease: Meta-analysis based on 56 genetic case-control studies of 12,563 cases and 12,622 controls.

Authors:  Huihui Ji; Dongjun Dai; Yunliang Wang; Danjie Jiang; Xingyu Zhou; Peipei Lin; Xiaosui Ji; Jinfeng Li; Yuzheng Zhang; Honglei Yin; Rongrong Chen; Lina Zhang; Mingqing Xu; Shiwei Duan; Qinwen Wang
Journal:  Exp Ther Med       Date:  2015-03-03       Impact factor: 2.447

3.  Amyloid beta peptide processing, insulin degrading enzyme, and butyrylcholinesterase.

Authors:  A S Balasubramanian
Journal:  Neurochem Res       Date:  2001-04       Impact factor: 3.996

4.  Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology.

Authors:  K M Mattila; J O Rinne; M Röyttä; P Laippala; T Pietilä; H Kalimo; T Koivula; H Frey; T Lehtimäki
Journal:  J Med Genet       Date:  2000-10       Impact factor: 6.318

5.  BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia.

Authors:  Alessandra Bizzarro; V Guglielmi; R Lomastro; A Valenza; A Lauria; C Marra; M C Silveri; F D Tiziano; C Brahe; C Masullo
Journal:  J Neural Transm (Vienna)       Date:  2010-03       Impact factor: 3.575

6.  A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Authors:  Agneta Nordberg; Clive Ballard; Roger Bullock; Taher Darreh-Shori; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-07

7.  Butyrylcholinesterase K variant and Alzheimer's disease risk: a meta-analysis.

Authors:  Zongcheng Wang; Yuren Jiang; Xi Wang; Yangsen Du; Dandan Xiao; Youchao Deng; Jinlian Wang
Journal:  Med Sci Monit       Date:  2015-05-16

8.  Butyrylcholinesterase interactions with amylin may protect pancreatic cells in metabolic syndrome.

Authors:  Shani Shenhar-Tsarfaty; Tal Bruck; Estelle R Bennett; Tsafrir Bravman; Einor Ben Aassayag; Nir Waiskopf; Ori Rogowski; Natan Bornstein; Shlomo Berliner; Hermona Soreq
Journal:  J Cell Mol Med       Date:  2011-08       Impact factor: 5.310

9.  Association between butyrylcholinesterase K variant and mild cognitive impairment in the Thai community-dwelling patients.

Authors:  Natsalil Pongthanaracht; Somchai Yanarojana; Darawan Pinthong; Supeenun Unchern; Amnuay Thithapandha; Prasert Assantachai; Porntip Supavilai
Journal:  Clin Interv Aging       Date:  2017-05-26       Impact factor: 4.458

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.